SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending after a significant stock decline, driven by first-quarter revenue guidance falling short of analyst expectations despite beating fourth-quarter earnings. The community is largely frustrated over the ongoing value destruction and management's stock-based compensation, while a few see the deep dip as an oversold opportunity.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after reporting strong earnings and an optimistic outlook, yet the stock saw a surprisingly flat after-hours reaction, leading to community speculation that market makers are suppressing price action to capitalize on options. The ongoing conversation also focuses on CEO Jensen Huang's unique perspective on AI's value in "tokens" and the impact of China's market.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce (CRM) is trending following its earnings report, where an increased dividend and a substantial $50 billion share buyback program are being heavily discussed, contrasting with mixed guidance and ongoing community debate about AI's potential impact on the SaaS sector; investors are divided between seeing a significant buying opportunity and remaining cautious.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending after reporting strong financial results, including significant revenue growth and strategic acquisitions like a major defense contract win, fueling community debate between those optimistic about its long-term potential and critics concerned by ongoing losses and high valuation.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is gaining attention after executing a U.S. Department of Energy agreement for Project TEFLA, advancing its Integral Molten Salt Reactor fuel production. Investors are actively comparing IMSR to other nuclear energy players, noting its unique technology and strategic position to address the massive energy demands of AI data centers, leading to discussions of its significant long-term potential.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as its long-term potential to power AI data centers with advanced nuclear reactors, supported by political tailwinds and a Meta deal, faces scrutiny from recent analyst downgrades, notable insider selling, and ongoing concerns about its pre-revenue status. The community is actively debating whether current dips represent a buying opportunity for future growth or reflect risks associated with its lengthy path to commercialization.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending after its nomlabofusp drug received FDA Breakthrough Therapy Designation for Friedreich's Ataxia, signifying a potential substantial improvement over existing treatments. This regulatory milestone, combined with an upsized public offering at $5.00 per share, is fueling community discussion around significant valuation upside and an accelerated approval pathway for its root-cause-targeting therapy, despite some debate on the impact of the offering.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is highly discussed following its Q4 earnings beat and a new $200 million OpenAI partnership, with community dialogue focusing on the slightly decelerated Q1/FY27 revenue guidance. Investors are actively debating the immediate monetization and tangible revenue contribution of its AI initiatives, weighing the bullish potential of increased data consumption against broader software sector re-evaluation spurred by AI disruption fears.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid unconfirmed merger talks with Automation Anywhere, fueling speculation about a potential buyout and short squeeze, even as the community remains divided on the company's past performance and future viability given its declining revenues.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending following a significant Q4 earnings beat driven by robust growth in USDC adoption and transaction volume, leading to community speculation about a potential short squeeze and its role as foundational digital dollar infrastructure amidst broader crypto market strength and ongoing regulatory discussions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Palvella said the study met its key secondary endpoint and all four additional secondary endpoints.</li><li>In the Phase 3 SELVA study, QTORIN rapamycin was generally well tolerated.&nbsp;</li><li>The company plans to submit an NDA to the U.S. FDA in the second half of 2026.</li></ul>Shares of Palvella Therapeutics Inc (PVLA) jumped nearly 37% on Tuesday, after the company reported positive topline results from its Phase 3 SELVA study, potentially paving the way for a FDA submission.&nbsp;The company said its lead candidate, QTORIN 3.9% rapamycin anhydrous gel, met its primary endpoint, showing a statistically significant improvement on the Microcystic Lymphatic Malformation Investigator Global Assessment scale.&nbsp;The study also met its key secondary endpoint and all four additional secondary endpoints, each demonstrating statistical significance in patients with microcystic lymphatic malformations (MLM), a rare vascular condition. MLM is a benign, fluid-filled cyst that can form under the skin, often on the neck or the head.<h2 class="st-heading-2">QTORIN Rapamycin Was Well Tolerated</h2>In the Phase 3 SELVA study, QTORIN rapamycin was generally well tolerated. Of the 50 patients who started treatment, 70% reported side effects, most of which were mild or moderate. Four serious adverse events were reported, but investigators said they were not related to the drug. The most common treatment-related issues were mild skin reactions at the application site.88% of the patients completed the 24-week study. Nearly all eligible participants chose to continue treatment in the extension phase.Based on these results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026, with potential U.S. approval expected in the first half of 2027, the firm added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ following the update, from ‘neutral’ a day earlier. Message volume on the platform was ‘extremely high’.<img src="https://news.stocktwits-cdn.com/PVLA_jpg_d1bfdadf88.webp" alt="PVLA.jpg">Year-to-date, the stock has gained around 16%&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did PVLA Stock Surge 37% Today?

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment 

Equity

<ul class="summary-bullets"><li>The contract encompasses a broad range of work areas that allows for the rapid delivery of innovative capabilities to the warfighter with increased speed and agility, it said in a statement.&nbsp;</li><li>Participation in the SHIELD IDIQ contract provides a contractual framework through which IonQ may compete for future task orders, subject to agency requirements and competitive selection processes.&nbsp;</li><li>IonQ has a history of supporting U.S. government research and development initiatives, including work with agencies such as DARPA, the U.S. Air Force Research Laboratory.&nbsp;</li></ul>IonQ on Monday announced that it won a contract from the Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program, which has a ceiling&nbsp;worth up to $151 billion.At the time of writing stock was up 2%.&nbsp;The contract encompasses a broad range of work areas that allows for the rapid delivery of innovative capabilities to the warfighter with increased speed and agility, it said in a statement.&nbsp;IonQ has a history of supporting U.S. government research and development initiatives, including work with agencies such as DARPA, the U.S. Air Force Research Laboratory, and organizations across the national security community.<h2 class="st-heading-2">SHIELD IDIQ</h2>IonQ is among more than 2,400 companies eligible to compete for future task orders issued under the SHIELD IDIQ contract framework.Participation in the SHIELD IDIQ contract provides a contractual framework through which IonQ may compete for future task orders, subject to agency requirements and competitive selection processes.&nbsp;“IonQ brings together a broad set of quantum technologies and supporting capabilities that reflect years of investment across computing, networking, sensing, and security,” said Niccolo de Masi, Chairman and CEO of IonQ. “We look forward to continuing our work with U.S. government partners across a range of research, development, and innovation programs.”<h2 class="st-heading-2">Other Firms In The Program</h2>AST SpaceMobile Inc. (ASTS) in January announced that it has been awarded a contract for the Missile Defense Agency SHIELD program.AST SpaceMobile was selected as a lead contractor, granting the company the opportunity to compete for a variety of upcoming projects. These projects could encompass research, development, engineering, prototyping, and overseeing vital systems for the Missile Defense Agency that support U.S. national security interests.<h2 class="st-heading-2">How Did Stocktwits’ Users React?</h2>Retail sentiment around IONQ trended in ‘bearish’ territory amid ‘low’ message volume.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of IONQ Inc.

Why Is IonQ Stock Surging After-Hours?

IonQ is among more than 2,400 companies eligible to compete for future task orders issued under the SHIELD IDIQ contract framework.

<ul class="summary-bullets"><li>Atomera’s stock offering is at a discount of 40% when compared to the closing price on Friday.</li><li>The company stated that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.</li><li>Atomera added that the stock offering is expected to close on or about Feb. 24, 2026.</li></ul>Atomera Inc. (ATOM) stock declined nearly 13% in Monday’s opening trade after the company announced the pricing of a new stock offering.Atomera announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share. This is at a discount of 40% from the stock’s closing price on Friday.<h2 class="st-heading-2">What Will Atomera Use The Funds For?</h2>Atomera stated in its announcement that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.The company added that the stock offering is expected to close on or about Feb. 24, 2026.Atomera reported its fourth-quarter (Q4) results earlier this month, posting a loss of $0.14 per share, in line with Wall Street expectations. The company reported revenue of $0.05 million, while the consensus estimate was $0.1 million, according to Stocktwits data.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ATOM">Atomera</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.Despite Atomera’s share price decline, one bullish user said it's a buying opportunity.<stembedurl>https://stocktwits.com/BioRocket/message/645608846</stembedurl>Another user stated they’re surprised by Atomera’s stock offering, noting that the company didn't need cash.<stembedurl>https://stocktwits.com/DinoMcnuggets/message/645607759</stembedurl><a href="https://stocktwits.com/symbol/ATOM">ATOM stock</a> is up 217% year-to-date and 9% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palo-alto-networks-removed-from-wedbush-best-ideas-list/cZRtp2lR4ya">Palo Alto Networks Removed From Wedbush’s ‘Best Ideas List’ — Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Atomera Incorporated logo is seen displayed on a smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

ATOM Stock Is Falling Today After Atomera Announces Stock Offering At A Deep Discount

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

<ul class="summary-bullets"><li>H.C. Wainwright analysts noted that they are “encouraged” by Ardelyx's new patent, which expires in November 2042.</li><li>Ardelyx announced that the U.S. Patent and Trademark Office had issued a patent for oral formulations of Tenapor, including its commercial formulations Ibsrela and Xpozah.</li><li>The company said during its earnings announcement that the FDA has now listed both Ibsrela and Xpozah in its Orange Book.</li></ul>Ardelyx Inc. (ARDX) shares are down nearly 8% in Friday’s pre-market session after the company’s fourth-quarter (Q4) earnings fell short of Wall Street expectations.However, analysts at H.C. Wainwright have hiked their price target for&nbsp;<a href="https://stocktwits.com/symbol/ARDX">Ardelyx shares</a> by 80%, increasing it to $18 from $10. The firm maintained its ‘Buy’ rating on the stock.H.C. Wainwright analysts noted that they are “encouraged” by Ardelyx being granted a new patent with expiration in November 2042.<h2 class="st-heading-2">What Is The Ardelyx Patent For?</h2>Ardelyx announced that the U.S. Patent and Trademark Office had issued a patent for oral formulations of Tenapor, including its commercial formulations Ibsrela and Xpozah.During an update earlier this month, Ardelyx stated that it will submit the patent to the U.S. Food and Drug Administration (FDA) for listing in its Approved Drug Products list, known as the Orange Book.The company said during its earnings announcement that the FDA has now listed both Ibsrela and Xpozah in the Orange Book.Ibsrela is a commercial formulation of Tenapor that is used in the treatment of irritable bowel syndrome with constipation. Xpozah is used to lower phosphate levels in the blood, mainly in people with chronic kidney disease on dialysis.“This is an important step in extending protections for our portfolio of first-in-class medicines in therapeutic areas where there continues to be significant unmet patient need,” said Ardelyx CEO Mike Raab.<h2 class="st-heading-2">Ardelyx’s Q4 Miss</h2>Ardelyx&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ardx-stock-slips-after-hours-as-q4-earnings-disappoint/cZRkXyCR4Di">reported</a> its Q4 results on Thursday, with earnings per share (EPS) at $0.0 on revenue of $125.2 million. Wall Street analysts expected an EPS of $0.01 on revenue of $118.05 million, according to Stocktwits data.The company said it expects full-year 2026 revenue from Ibsrela to be in the $410 million to $430 million range, while Xpozah revenue is estimated at $110 million to $120 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/ARDX">Ardelyx</a> trended in the ‘extremely bullish’ territory at the time of writing, with message volumes at ‘high’ levels.One user said that, historically, Ardelyx’s management has tended to underpromise and overdeliver. “Long-term thesis remains intact,” they said.<stembedurl>https://stocktwits.com/fmcruz/message/645418378</stembedurl><a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> is up 16% year-to-date and 6% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-strike-on-iran-imminent-trump-10-day-window-what-bettors-think-prediction-markets/cZRNcKHR4x7">Will US Strike Iran Anytime Soon Given Trump's 10-Day Window For More Clarity? Here's What Bettors Think Amid The Military Build-Up In Middle East</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%?

Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

<ul class="summary-bullets"><li>The agency’s assessment was based on the company’s Phase 2 data package.</li><li>The FDA supported the use of Clinical Dementia Rating Scale-Sum of Boxes, a scale used to determine dementia severity.</li><li>INmune will enroll about 300 participants over nine months to confirm efficacy before expanding to a 1,000-patient Phase 3 trial.</li></ul>INmune Bio, Inc (INMB) stock gave up some of its pre-market gains to trade 3% higher on Thursday morning, after the company said it has received official U.S. Food and Drug Administration (FDA) meeting minutes confirming regulatory alignment on its integrated Phase 2b/3 development plan for XPro1595, a potential therapy for early Alzheimer’s disease.The FDA supported INmune Bio’s precision medicine strategy, which uses a trial design to identify patients whose inflammatory biomarker profiles are tied to soluble tumor necrosis factor (TNF) signalling, the treatment’s biological target.The agency’s assessment was based on the company’s Phase 2 data package, which included cognitive and biomarker findings.“XPro1595 represents a differentiated approach to Alzheimer’s disease, based on precision patient selection and selective immune modulation, with a favorable safety profile that included zero cases of ARIA in our Phase 2 study,” said David Moss, INmune Bio’s CEO.<h2 class="st-heading-2">FDA Approval Details</h2>The FDA supported the use of the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) as the primary endpoint, a scale used to assess dementia severity and track progression. It also did not object to INmune Bio’s plan to enroll patients identified by key inflammation-related biomarkers linked to the drug’s target.The company said that the Phase 2b part will feature a nine-month evaluation period to build the clinical foundation for a subsequent Phase 3 study. INmune will enroll about 300 participants over nine months to confirm efficacy before expanding to a 1,000-patient Phase 3 trial lasting 18 months.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned’ bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/INMB_jpg_241e60ecf9.webp" alt="INMB.jpg">One user noted a tepid market reaction and said that it was an “excellent time to add” the stock to their portfolio.<stembedurl>https://stocktwits.com/10baggerPete/message/644778292</stembedurl>Another user said the company was “moving in the right direction.”<stembedurl>https://stocktwits.com/bioinvestorrr/message/644769951</stembedurl><a href="https://stocktwits.com/symbol/INMB">INMB shares</a> have declined around 0.6% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-retail-sales-slump-in-january/cZRTn3fR4rK">Tesla’s China Retail Sales Slump 45% In January: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial?

The FDA meeting minutes suggest INmune Bio’s late-stage Alzheimer’s trial design is on track.

<ul class="summary-bullets"><li>Ouster funded the deal through roughly $35 million in cash and 1.8 million shares.</li><li>The acquisition will be treated as a business combination, and StereoLabs will operate as a wholly owned unit of Ouster.</li><li>Ouster will become a single-source provider for synchronized lidar and stereo camera data.</li></ul>Ouster, Inc. (OUST) garnered retail traders’ attention in premarket trading on Monday after announcing the completion of the acquisition of AI vision specialist StereoLabs SAS earlier this month.The deal will combine Ouster’s digital lidar with StereoLabs’ advanced camera technology, AI compute, sensor fusion, and perception software to create what Ouster describes as the first end-to-end platform for Physical AI applications.<a href="https://stocktwits.com/symbol/OUST">OUST</a> was among the top trending tickers on Stocktwits at the time of writing, with the stock climbing 2% higher.<h2 class="st-heading-2">StereoLabs Deal Details: Cash, Stock, And 2026 Consolidation</h2>Ouster funded the deal through roughly $35 million in cash and 1.8 million shares, including 0.7 million shares scheduled for release over four years. The acquisition will be treated as a business combination, and StereoLabs will operate as a wholly owned unit of Ouster. StereoLabs’ financial results will be consolidated into Ouster’s statements beginning in the first quarter of fiscal 2026.<h2 class="st-heading-2">StereoLabs Adds Profitable Revenue Stream</h2>StereoLabs generated around $16 million in unaudited revenue in 2025 and brings a positive earnings before interest, tax, depreciation and amortization (EBITDA) business.<h2 class="st-heading-2">New Use Cases: Robotics, Automation, Smart Infrastructure</h2>Ouster will become a single-source provider for synchronized lidar and stereo camera data. The combination is expected to improve software capabilities, expand Ouster’s reach across robotics, industrial automation, and smart infrastructure, and open up emerging use cases such as humanoid robotics and visual inspection.“This acquisition builds on Ouster’s momentum and positions us as the foundational end-to-end sensing and perception platform for Physical AI,” said Ouster CEO Angus Pacala.<h2 class="st-heading-2">Retail Sentiment On Stocktwits Improves</h2>Retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/Ouster_jpg_3db8985072.webp" alt="Ouster.jpg">One user expects the stock to rise all the way right up to its earnings on March 2.<stembedurl>https://stocktwits.com/Ashtonmar/message/644427184</stembedurl>Year-to-date, the stock has shed around 12%, though its gains over the past year exceed 86%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/coinbase-super-bowl-ad-backstreet-boys-crypto-mainstream/cZbHwueR48H">Coinbase Super Bowl Commercial Taps Into Backstreet Boys Nostalgia – Marking Crypto’s Cautious Return To Big-Game Ads</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did OUST Stock Catch Retail Attention In Pre-Market Today? 

The company announced that it completed the acquisition of AI vision specialist StereoLabs SAS earlier this month.

This Small-Cap Sensor Stock Is Making A Big Bet On Physical AI: Retail Traders Are Watching Closely 

<ul class="summary-bullets"><li>For Genius Sports, the transaction is expected to be immediately accretive to group adjusted core profit and free cash flow conversion.&nbsp;</li><li>Genius Sports said its prelim group revenue for FY25 is of $669 million, reflecting 31% year-on-year growth.</li><li>It also expects to generate group revenue of approximately $810-820 million in FY26.</li></ul>Genius Sports (<a href="https://stocktwits.com/symbol/GENI">GENI</a>) shares plunged on Thursday after it announced it has entered into a definitive agreement to acquire Legend, a global, digital sports and gaming media network.Shares plunged 26.5% to $6.28 at the time of writing and garnered retail chatter around the deal.<h2 class="st-heading-2">Deal Details</h2>Genius Sports said it is acquiring Legend in a transaction valued at up to $1.2 billion, including $900 million payable at closing and an earnout of up to $300 million.For Genius Sports, the transaction is expected to be immediately accretive to group adjusted core profit margins and free cash flow conversion while maintaining at least 20% group revenue compound annual growth rate (CAGR) through 2028.&nbsp;On a 2026 annualized pro forma basis; after giving effect to the acquisition, the combination is expected to position Genius to achieve approximately $1.1 billion in group revenue, $320-330 million in group adjusted core profit with approximately 50% free cash flow conversion.“This deal accelerates our strategic and financial objectives, supercharges fan monetization, and builds a fully integrated sports and gaming media network,” said Mark Locke, CEO of Genius Sports.<h2 class="st-heading-2">Prelim FY25 Earnings And FY26Outlook</h2>The company on Thursday also reported its preliminary unaudited financial results for the fiscal year ended December 31, 2025. It said its prelim group revenue is $669 million, reflecting 31% year-on-year growth.Genius Sports also expects to generate group revenue of approximately $810-820 million, and group adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of approximately $180-190 million in 2026 on a standalone basis.&nbsp;Group Revenue of $1.6 billion, representing approximately 21% compound annual growth rate (CAGR) from 2026 to 2028, as the acquisition and integration of Legend will also set a higher performance benchmark for 2028, it said in a statement.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GENI trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user on Stocktwits opined that they are not sure that GENI needed to inject this risk as its business was doing well.&nbsp;<stembedurl>https://stocktwits.com/Windy007/message/644135227</stembedurl>Another user said they were not expecting the company to strike a more than $1billion worth deal.<stembedurl>https://stocktwits.com/Jblack500/message/644132457</stembedurl>Shares in the company have fallen 34% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-coin-stock-down-today/cZbZWG7R4Vz">Why is COIN Stock Falling More Than 8% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Shares of GENI plunged 26.5% to $6.28 at the time of writing and garnered retail chatter around the deal.

Genius Sports’ Stock Is Down 26% Today – Why Is Retail Wary?

 Genius Sports said it is acquiring Legend in a transaction valued at up to $1.2 billion, including $900 million payable at closing and an earnout of up to $300 million.

<ul class="summary-bullets"><li>The first product on the list is Hydrelix, a Type 1 collagen powder that provides the bioactive components of collagen at the wound site.</li><li>The second product is NovaForm Wound Matrix, a bioglass- and collagen-based wound dressing intended for the management of partial- and full-thickness wounds.</li><li>Summit will also distribute G4Derm Plus, a flowable peptide matrix engineered for rapid, protected wound closure.</li></ul>MiMedx Group Inc. (MDXG) shares gained around 5% in Wednesday morning’s trade after the company entered into an exclusive distribution agreement with Summit Products Group for three of its 510(k) cleared products.According to the agreement, Summit will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MDXG">MiMedx</a> was in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">What Will Summit Distribute?</h2>The three products included in the agreement are intended to care for and enhance the closure of wounds.The first product in the list is Hydrelix, which is a Type 1 collagen powder that allows the bioactive components of collagen to be readily available at the wound site, facilitating a more direct and efficient therapeutic effect.The second product is NovaForm Wound Matrix, which is a bioglass and collagen-based wound dressing intended for use in the management of partial and full-thickness wounds. NovaForm can be used for pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds.&nbsp;The company says NovaForm is designed to maintain a moist environment that supports the body’s natural healing process while protecting the wound.Lastly, Summit will also distribute G4Derm Plus, a flowable peptide matrix engineered for rapid, protected wound closure, spurring tissue regrowth, and controlling bioburden. The company stated that G4Derm Plus mimics the human extracellular matrix (ECM) and acts as a barrier against bacteria.“These are innovative xenograft and synthetic products that strengthen our ability to serve the Surgical &amp; Wound markets,” said MiMedx’s Chief Commercial Officer, Kim Moller.<h2 class="st-heading-2">What Does MiMedx Do?</h2>MiMedx is a Marietta, Georgia-based company with a portfolio of surgical and wound care products designed to help clinicians manage chronic and other hard-to-heal wounds.In December 2025, the company entered into an exclusive agreement with Regen Lab USA LLC to distribute the latter’s RegenKit-Wound Gel in the U.S.<a href="https://stocktwits.com/symbol/MDXG">MDXG stock</a> is down 24% year-to-date and 40% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-openai-in-talks-to-customize-ai-models/cZbjTCvR4Zu">Amazon, OpenAI In Talks To Customize AI Models To Power E-commerce Giant's Products Such As Alexa: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products

According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.

<ul class="summary-bullets"><li>The report alleged that golfer Phil Mickelson was among the select investors.</li><li>Sable said it is providing documents and cooperating with requests from the government.</li><li>Sable also entered into a sales agreement with TD Securities and Jefferies to sell up to $250 million of common stock.</li></ul>Shares of Sable Offshore Corp. (SOC) plunged over 10% on Tuesday after the company revealed it had received subpoenas from the U.S. Attorney’s Office for the Southern District of New York and the SEC, following a Hunterbrook investigation alleging selective disclosure of material information to certain investors.The company also announced a $250 million share sale agreement.In an SEC filing, Sable said it received the subpoenas on December 2, weeks after Hunterbrook’s October 31 report. The report alleged that CEO Jim Flores shared multiple updates privately with select investors, including golfer Phil Mickelson.One such update was that the company may need to raise up to $200 million in equity by the end of 2025. Sable said it is providing documents and cooperating with government requests.<h2 class="st-heading-2">Sable’s $250 Million Share Sale Plan</h2>Sable also entered into a sales agreement with TD Securities (USA) LLC and Jefferies LLC, which will allow the company to sell up to $250 million of its common stock through an at-the-market (ATM) offering.&nbsp;Last month, California Attorney General Rob Bonta sued the Donald Trump administration over the planned restart of two onshore oil pipelines owned and operated by Sable. The lawsuit challenged federal orders that assert exclusive jurisdiction over the Las Flores pipelines. Bonta argued the pipelines run within California and should remain under state oversight, citing environmental risks.The lines have been shut down for a decade following the 2015 Refugio Beach oil spill, which released hundreds of thousands of gallons of crude.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bearish’ from ‘bearish’ a day earlier. One user said the stock’s decline was an overreaction by the market.<stembedurl>https://stocktwits.com/s66666/message/643781913</stembedurl>Year-to-date, <a href="https://stocktwits.com/symbol/SOC">SOC shares</a> have declined around 25%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-tirx-stock-surge-today/cZbiyMWR4m9">This Nano-Cap Insurance Stock Surged Over 200% Today – What Is The Bitcoin Connection?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

SOC Stock Declines 10% – What Are The Factors Driving The Selloff?

The company disclosed that it has received subpoenas from the U.S. Attorney’s Office for the Southern District of New York and the SEC on reports of selective disclosure of material information to certain investors.

Current Price	$338.85
Prev Close	$337.45
Open	$339.92
Dividend Yield	N/A
50-Day Moving Average	$337.10
Beta	N/A
Avg. Volume	639,715.80
PE Ratio	N/A

52-Week High	$355.34
52-Week Low	$219.19
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IWO
iShares Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWO News

IWOiShares Russell 2000 Growth ETF